Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
56 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Pipeline Review, H2 2016', provides in depth analysis on Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted pipeline therapeutics. The report provides comprehensive information on the Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - The report reviews Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics and enlists all their major and minor projects - The report assesses Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) Overview 7 Therapeutics Development 8 Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Products under Development by Stage of Development 8 Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Products under Development by Therapy Area 9 Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Products under Development by Indication 10 Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Products under Development by Companies 13 Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Products under Development by Universities/Institutes 15 Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Therapeutics Assessment 17 Assessment by Monotherapy/Combination Products 17 Assessment by Mechanism of Action 18 Assessment by Route of Administration 20 Assessment by Molecule Type 21 Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Companies Involved in Therapeutics Development 22 Catalyst Biosciences, Inc. 22 H. Lundbeck A/S 23 NeuroDerm Ltd. 24 Saniona AB 25 Suven Life Sciences Ltd. 26 Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Drug Profiles 27 (nicotine + opipramol hydrochloride) - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 NS-9283 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Small Molecule to Agonize Alpha 4Beta 2 and Alpha 6Beta 2 Neuronal Nicotinic Receptor for Smoking Cessation - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Small Molecule to Antagonize CHRNB2 and CHRNA4 for Psychiatric Disorders - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Small Molecule to Antagonize nAChR Alpha-4 Beta-2 for CNS Disorders - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 Small Molecule to Antagonize nAChR Alpha-4 Beta-2 for Obesity and Metabolic Disorders - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Small Molecule to Antagonize nAChR Alpha-4 Beta-2 for Pain - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 Small Molecules to Antagonize CHRNB2 and CHRNA4 for Smoking Cessation - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Small Molecules to Antagonize nAChR Alpha-4 Beta-2 for Neurological and Psychiatric disorders - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 SUVN-911 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 TC-8831 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 varenicline tartrate - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Dormant Projects 40 Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Discontinued Products 42 Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Featured News & Press Releases 43 May 23, 2016: CHAMPIX (Varenicline) European Union Label Updated To Include New Safety And Efficacy Data From The EAGLES Clinical Trial Following Endorsement From CHMP 43 Apr 22, 2016: CHANTIX/CHAMPIX (Varenicline) Results From The Largest Global Clinical Trial Of Smoking Cessation Medicines Published In The Lancet 43 Sep 04, 2015: Quit-smoking drug safer than thought 45 Mar 09, 2015: FDA updates label for stop smoking drug Chantix 46 Mar 09, 2015: Suven Life secures One (1) Product Patent each in Eurasia and Israel 47 Oct 06, 2014: US District Court Dismisses All Claims Related To Pfizer's Chantix 47 Jan 21, 2014: CHANTIX/CHAMPIX (varenicline) Demonstrates Smoking-Cessation Efficacy In Smokers Unwilling or Unable To Quit Abruptly 47 Jun 03, 2013: NIH Researchers Find Varenicline As Promising Treatment For Alcohol Dependence 48 Feb 28, 2013: Pfizer Pays $273m For Settlement Of Lawsuits Related To Anti-smoking Drug Chantix 49 Jan 24, 2013: Pfizer's Chantix Demonstrates Efficacy In Smokers Who Previously Attempted To Quit Smoking With Chantix 50 Dec 12, 2012: FDA Provides Updated Information Of Safety Review On Risk Of Cardiovascular Adverse Events Associated With Pfizer's Chantix 51 Oct 16, 2012: Pfizer Completes Efficacy And Safety Study Of Smoking Cessation Drug Chantix 51 Jan 19, 2012: Health Canada Completes Review Of Pfizer's Smoking-Cessation Drug, Champix 52 Jul 21, 2011: European Medicines Agency Confirms Positive Benefit-Risk Balance For Champix 53 Jul 21, 2011: European Medicines Agency Confirms Positive Benefit-Risk Balance For Pfizer's Champix 53 Appendix 55 Methodology 55 Coverage 55 Secondary Research 55 Primary Research 55 Expert Panel Validation 55 Contact Us 55 Disclaimer 56
List of Tables
Number of Products under Development for, H2 2016 8 Number of Products under Development by Therapy Area, H2 2016 9 Number of Products under Development by Indication, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Early Stage Products, H2 2016 12 Number of Products under Development by Companies, H2 2016 13 Products under Development by Companies, H2 2016 14 Number of Products under Investigation by Universities/Institutes, H2 2016 15 Products under Investigation by Universities/Institutes, H2 2016 16 Assessment by Monotherapy/Combination Products, H2 2016 17 Number of Products by Stage and Mechanism of Action, H2 2016 19 Number of Products by Stage and Route of Administration, H2 2016 20 Number of Products by Stage and Molecule Type, H2 2016 21 Pipeline by Catalyst Biosciences, Inc., H2 2016 22 Pipeline by H. Lundbeck A/S, H2 2016 23 Pipeline by NeuroDerm Ltd., H2 2016 24 Pipeline by Saniona AB, H2 2016 25 Pipeline by Suven Life Sciences Ltd., H2 2016 26 Dormant Projects, H2 2016 40 Dormant Projects (Contd..1), H2 2016 41 Discontinued Products, H2 2016 42
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
